

**Olympus Launches Latest EBUS Bronchoscope BF-UCP190F  
in EMEA and APAC**

Thin outer diameter and strong upward angulation for extended diagnostic reach and precision

TOKYO, September 1, 2025 – [Olympus Corporation](#) (Olympus), a global MedTech company committed to making people's lives healthier, safer and more fulfilling, today announced the launch of its latest endobronchial ultrasound (EBUS) bronchoscope BF-UCP190F. Following its availability across EMEA and major Asia-Pacific<sup>1</sup> (APAC) markets starting September, the bronchoscope is scheduled to launch in Japan in the following months.



EVIS EUS ULTRASOUND BRONCHOFIBERVIDEOSCOPE OLYMPUS BF-UCP190F

Lung cancer continues to be the foremost cause of cancer-related mortality globally, responsible for approximately 1.8 million deaths each year<sup>2</sup>. Timely and accurate diagnosis and staging are essential to guide appropriate treatment and improve patient outcomes<sup>3,4</sup>. However, current technologies for sampling lesions and lymph nodes in segmental and sub-segmental airways lack real-time visualization during sampling<sup>5</sup>, which may contribute to diagnostic delays and inaccuracies.

The BF-UCP190F is used to perform endobronchial ultrasound-guided needle aspiration (EBUS-TBNA), a procedure in which a specimen is collected by inserting a special needle while confirming the target site on the ultrasound image in real-time. Pathological diagnosis of the collected specimen supports to establish the diagnosis of various lung diseases such as lung cancer and can inform the proper treatment pathway for patients through further molecular analysis.

Furthermore, the BF-UCP190F provides a slim design with a short distal-end and enhanced scope maneuverability to address the challenges physicians face in precision sampling of primary lesions in the segmental and sub-segmental region of the lung, as well as extending EBUS-TBNA-guided staging to lymph nodes in the peripheral zone that were not accessible so far<sup>6</sup>. This innovation enables precise tissue acquisition in deeper lung areas, supporting more accurate diagnostic assessment.

## 1. Extended Reach to Deeper Lung Regions



Comparison of BF-UCP190F, BF-UC190F, and BF-UC180F

With a small outer diameter of 5.9mm, the BF-UCP190F expands the accessibility to deeper lung regions, reaching significantly farther in most segmental bronchi, including left and right upper and middle lobes, and improving puncture success in segmental and sub-segmental bronchial areas compared to the BF-UC190F<sup>6</sup>.

## 2. Expanded Access



Upward and downward angulation of BF-UCP190F

Furthermore, the BF-UCP190F offers an upward angulation of 170 degrees - 10 degrees wider than the BF-UC190F - to empower access to challenging locations within the lung for precise diagnostic sampling<sup>6</sup>.

## 3. Optimized View & Maneuverability

With a 14-degree forward oblique view angle and a redesigned distal end, the BF-UCP190F offers enhanced visibility and maneuverability, simplifying navigation within the tracheobronchial tree.

With the BF-UCP190F, Olympus continues to lead in EBUS technology, equipping physicians with a more complete solution for lung cancer diagnosis and staging while maintaining seamless workflow integration with existing Olympus EBUS platforms.

- <sup>1</sup> Hong Kong, Australia, New Zealand
- <sup>2</sup> Zhou J, Xu Y, Liu J, Feng L, Yu J, Chen D. Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN. *Cancer Epidemiol.* 2024;93:102693. doi:10.1016/j.canep.2024.102693
- <sup>3</sup> Guirado M, Fernández Martín E, Fernández Villar A, Navarro Martín A, Sánchez-Hernández A. Clinical impact of delays in the management of lung cancer patients in the last decade: systematic review. *Clin Transl Oncol.* 2022 Aug;24(8):1549-1568. doi: 10.1007/s12094-022-02796-w. Epub 2022 Mar 7. PMID: 35257298; PMCID: PMC8900646.
- <sup>4</sup> Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2017;28(suppl\_4):iv1-iv21. doi:10.1093/annonc/mdx222
- <sup>5</sup> Silvestri GA, Bevil BT, Huang J, et al. An Evaluation of Diagnostic Yield From Bronchoscopy: The Impact of Clinical/Radiographic Factors, Procedure Type, and Degree of Suspicion for Cancer. *Chest.* 2020;157(6):1656-1664. doi:10.1016/j.chest.2019.12.024
- <sup>6</sup> Takashima Y, Shinagawa N, Shoji T, et al. Evaluating the Efficacy of Thin Convex-probe Endobronchial Ultrasound Bronchoscope in Cadaveric Models. *J Bronchology Interv Pulmonol.* 2025;32(3):e01015. Published 2025 May 21. doi:10.1097/LBR.0000000000001015

## About Olympus

At Olympus, we are committed to Our Purpose of making people's lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit <https://www.olympus-global.com/> and follow our global [LinkedIn](#) and [X](#) accounts.